China’s Haisco forms immunology biotech with up to $1.5B from American VCs

Haisco Pharmaceutical Group has been on a deal hot streak this year, inking major deals with Eli Lilly, AbbVie and more. The new company will take on one of Haisco’s core immunology assets.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top